Skip to main content
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing.

Detection Principle
ImmunoAssay-Antibody
Target
IgG vs S, IgG vs N, IgA vs S (Euroimmun); IgA, IgM vs N (Roche); IgM, IgG vs S, N (Snibe/Medac); IgG vs N (Abbott)
Testing Method Category
Mixed
Testing Method
kits (Euroimmun, Snibe/Medac, Roche and Abbott)
Testing Method - Additional Info
Chemiluminescent microparticle assay (Abbott); Chemoluminescence immunoassay platform (Snibe/Medac) ; Electrochemiluminescence immunoassay (Roche); Enzyme-linked immunosorbent assay (Euroimmun)
Reported Performance
Sensitivity: 81.5% (Abbott), 95% (Roche), 91.6% (Euroimmun IgG-S), 79.8% (Euroimmun IgA), 86.6% (Euroimmun IgG-N), 56.9% (Snibe/Medac IgG), 25.9% (Snibe/Medac IgM); Specificity: 100% (Abbott), 100% (Roche), 100% (Euroimmun IgG-S), 93.6% (Euroimmun IgA), 97.3% (Euroimmun IgG-N), 100% (Snibe/Medac IgG), 97.2% (Snibe/Medac IgM); PPV: 100% (Abbott), 100% (Roche), 100% (Euroimmun IgG-S), 93.1% (Euroimmun IgA), 97.2% (Euroimmun IgG-N), 100% (Snibe/Medac IgG), 88.2% (Snibe/Medac IgM); NPV: 83.3% (Abbott), 94.8% (Roche), 91.7% (Euroimmun IgG-S), 81.1% (Euroimmun IgA), 87% (Euroimmun IgG-N), 74.2% (Snibe/Medac IgG), 61.9% (Snibe/Medac IgM)
Sample Size
229 samples
Peer-reviewed
yes

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements